Esperion Therapeutics Inc. (NASDAQ:ESPR) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued on Monday.

According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “

Other analysts have also recently issued reports about the company. Vetr lowered Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 price objective for the company. in a research note on Monday, July 18th. Needham & Company LLC reissued a “buy” rating and set a $25.00 price objective (down from $77.00) on shares of Esperion Therapeutics in a research note on Wednesday, June 29th. Lake Street Capital reduced their price objective on Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday, June 29th. Citigroup Inc. reissued a “buy” rating and set a $22.00 price objective (down from $36.00) on shares of Esperion Therapeutics in a research note on Wednesday, June 29th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $64.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, September 22nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $26.36.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR) opened at 12.38 on Monday. The company has a 50-day moving average price of $12.43 and a 200 day moving average price of $13.85. Esperion Therapeutics has a 1-year low of $9.58 and a 1-year high of $30.41. The firm’s market capitalization is $279.17 million.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. During the same period last year, the firm posted ($0.55) EPS. Analysts expect that Esperion Therapeutics will post ($3.37) earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the company. Stifel Financial Corp increased its stake in Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,438 shares during the last quarter. Pentwater Capital Management LP increased its stake in Esperion Therapeutics by 6.6% in the second quarter. Pentwater Capital Management LP now owns 1,518,000 shares of the biopharmaceutical company’s stock worth $14,998,000 after buying an additional 94,000 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in Esperion Therapeutics by 315.0% in the second quarter. Parametric Portfolio Associates LLC now owns 42,903 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 32,566 shares during the last quarter. KCG Holdings Inc. bought a new stake in Esperion Therapeutics during the second quarter worth $413,000. Finally, Senzar Asset Management LLC bought a new stake in Esperion Therapeutics during the second quarter worth $2,171,000. 65.23% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.